XBiotech Announces Granting of European Patent for Treatment of Inflammatory Skin Diseases
Broad European Patent Issued Supports XBiotech’s Skin Disease Program for Monoclonal Antibody Bermekimab
AUSTIN, Texas, Sept. 26, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that the European Patent Office has granted XBiotech a patent (Patent Number EP2694107) that covers the use of bermekimab as a treatment for inflammatory skin diseases. The patent includes data from studies showing that antibodies which specifically neutralize the activity of interleukin-1alpha (IL-1α) can reduce skin inflammation and treat inflammatory skin diseases. XBiotech has conducted a number of clinical trials in dermatology using bermekimab (an anti- IL-1α antibody), including ongoing studies in hidradenitis suppurativa and atopic dermatitis. XBiotech has also published clinical findings for the use of bermekimab for treatment of psoriasis and acne. The development of bermekimab for the treatment of inflammatory skin disorders is an important part of XBiotech’s commercialization programs.
Stanley Kim, Ph.D., J.D., XBiotech’s Corporate Vice President of Intellectual Property, stated, “I am pleased that the European Patent Office acknowledged the significance of XBiotech’s contribution to this field by granting this patent with broad claims. As a pioneer in IL-1α research, XBiotech has developed a significant worldwide patent portfolio for the use of bermekimab to prevent and treat inflammatory skin diseases as well as other conditions involving sterile inflammation.”
This patent issuance further broadens XBiotech’s patent portfolio as it relates to bermekimab and its potential to treat inflammatory skin disorders through IL-1α blockade. XBiotech previously conducted clinical studies with bermekimab to treat dermatological conditions including psoriasis1, acne2 and hidradenitis suppurativa3. The Company is currently conducting two separate open label, phase 2, multi-center studies evaluating a subcutaneous formulation of bermekimab in pre-filled syringes for treatment of atopic dermatitis and hidradenitis suppurativa.
The grant of this patent in Europe is in addition to patents granted in the US, Australia, and Japan. The Company’s patent portfolio also includes several pending U.S. and foreign applications directed to dermatologic pathologies. The Company plans to continue to pursue inflammatory skin disorder indications as it further strengthens its clinical pipeline.
About 85 million Americans sought treatment from a physician for skin disease in 2013, with an estimated direct health care cost of $75 billion4. The economic impact and prevalence of skin disease is on a similar magnitude as other major diseases affecting the US population, including diabetes and cardiovascular disease. Consequently, revenues from new biological drugs used to treat skin diseases are growing rapidly. XBiotech believes bermekimab may emerge as a major new therapy for skin disease.
Dr. Kim has been XBiotech’s chief intellectual property counsel for over 10 years. Prior to joining XBiotech, Dr. Kim led his law firm's patent and life sciences practices. Dr. Kim is a registered patent attorney, experienced in procuring domestic and foreign patents, licensing and joint ventures, intellectual property opinions and due diligence, strategic patent portfolio development, and intellectual property litigation matters. Dr. Kim holds a bachelor's degree in Biology from Bowdoin College, a Ph.D. in Microbiology and Immunology from the University of Miami, and a law degree from Suffolk University.
About True Human™ Therapeutic Antibodies
XBiotech’s True Human™ antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com .
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
1 Coleman KM et al. Open-Label Trial of MABp1, a True Human Monoclonal Antibody Targeting Interleukin 1⍺, for the Treatment of Psoriasis. JAMA Dermatol. 2015 May;151(5):555-6.
2 Carrasco D et al. An Open Label, Phase 2 Study of MABp1 Monotherapy for the Treatment of Acne Vulgaris and Psychiatric Comorbidity. J Drugs Dermatol. 2015 Jun;14(6):560-4.
3 Kanni T et al. MABp1 Targeting Interleukin-1Alpha for Moderate to Severe Hidradenitis Suppurativa not Eligible for Adalimumab: A Randomized Study. J Invest Dermatol. 2018 Apr; 138(4):795-801.
4 Lim et al. The burden of skin disease in the United States. J. Am Acad Dermatol. 2017 May; 76 (5), 958-972.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Constellation Brands CEO Bill Newlands Signs CEO Action for Diversity & Inclusion Pledge20.6.2019 15:00:00 CEST | Pressemelding
VICTOR, N.Y., June 20, 2019 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, announced today that that Bill Newlands, president and chief executive officer, is joining CEO Action for Diversity & Inclusion™ - the largest CEO-driven business commitment to advance diversity and inclusion within the workplace. The CEO Action for Diversity & Inclusion recognizes that change often happens when there’s support at the executive level. More than 600 CEOs of the world’s leading companies and business organizations are leveraging their voices to advance diversity and inclusion in the workplace by placing individual accountability on all—leaders and employees—to create inclusive environments. “At Constellation, we work hard to foster an inclusive culture that is characterized by diversity in background and thought, and that reflects our consumers and the communities where we live and work,” said Newlands. “Signing the CEO Action for Diversit
Radient Technologies Inc. Provides Update on Progress of Cannabis and Hemp Extraction Facilities and Issues Shares for Services20.6.2019 13:30:00 CEST | Pressemelding
EDMONTON, Alberta, June 20, 2019 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF) is pleased to announce it has awarded the mandate for the second phase of the construction of its Edmonton III manufacturing facility to Fillmore Construction Management Inc. (“Fillmore”). Construction is well underway, with footings and foundation work having been completed, and the structural component of the building now in progress and on schedule. Fillmore was selected by Radient due to its extensive previous experience developing food processing and GMP approved manufacturing plants. Edmonton III is Radient’s expanded capacity cannabis and hemp processing line that is expected to have a total annual throughput capacity of 280,000 kg/year of cannabis, and 2,800,000 kg/year of hemp upon completion in calendar 2020. Radient completed its first commercial extraction run for Aurora Cannabis Inc. (“Aurora”) (TSX: ACB; NYSE: ACB) in May 2019 at its
TeraRecon Receives First-of-Kind FDA Determination20.6.2019 11:00:00 CEST | Pressemelding
DURHAM, N.C., June 20, 2019 (GLOBE NEWSWIRE) -- Advanced visualization and artificial intelligence (AI) technology provider, TeraRecon, today announced it has successfully completed an FDA regulatory review of its Northstar™ AI Results Explorer, for which the technology and the determination are both firsts-of-kind in the medical imaging industry. Northstar is designed to work alongside the company’s EnvoyAI™ interoperability platform which includes FDA-cleared 3rd party content listed on its EnvoyAI Exchange marketplace. The Northstar determination letter reinforces the company’s commitment to regulatory and quality standards along with transparency in the field of medical imaging artificial intelligence. The Northstar AI Results Explorer provides an engaging physician user experience which can be integrated into the clinical systems already used throughout the health enterprise. Now with full commercial availability, Northstar can provide physicians an important way to accept, reject
Appian Named A Leader in Digital Process Automation for Deep Deployments Report by Independent Research Firm19.6.2019 16:28:00 CEST | Pressemelding
RESTON, Va, June 19, 2019 (GLOBE NEWSWIRE) -- Appian (NASDAQ: APPN) today announced it has been named a leader in “The Forrester Wave™: Software For Digital Process Automation For Deep Deployments, Q2 2019” report (“DPA Deep”). In Forrester’s four market segments for rapid application development, DPA Deep platforms “excel at the high end of process complexity but may also be the right solution to meet the needs for a wide-deployment, low-code standard” in an organization. In Forrester’s evaluation, Appian tied for the top score in the Current Offering category (including criteria for user experience development tools; process and flow design; digital decisioning, and robotic process automation). Appian also received among the second-highest scores in the Strategy category (including criteria like vision and strategy, commercial model, partners and training, community, and marketplace). The report notes that “Appian is a low-code vendor that thrives in complex process environments.” Th
Seaborn Networks announces new IP & Ethernet Services for Brazil and U.S. market19.6.2019 14:30:00 CEST | Pressemelding
BOSTON, June 19, 2019 (GLOBE NEWSWIRE) -- Seaborn Networks (“Seaborn”), a leading developer-owner-operator of subsea fiber optic cable systems, today announced that it will be delivering industry leading performance with new IP Service offerings comprising of diverse Ethernet Service and IP Service solutions addressing the market’s demand for rapidly deployed and highly stable global Ethernet & IP based needs between North and South America. IP Service offerings will include IP Transit, Remote Peering, Cloud Connect and Enterprise DIA solutions. Seaborn’s IP Services are offered under a minimal commitment with the ability to utilize additional bandwidth on a pay-as-you-use basis. Seaborn’s Ethernet Service offerings include E-Line, E-LAN and E-Tree capabilities with options for protected service depending on the Class of Service (CoS) selected. Industry leading SLA’s are provided on all IP and Ethernet services. “In today’s fast paced, highly complex communications environment, busines
Standard Lithium Announces Positive Preliminary Economic Assessment and Upgrading of Mineral Resource at Its Southern Arkansas Lithium Brine Project19.6.2019 09:00:00 CEST | Pressemelding
VANCOUVER, British Columbia, June 19, 2019 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLL) (OTCQX: STLHF) (FRA: S5L), is pleased to announce the results of a Preliminary Economic Assessment (PEA) of its 150,000 acre project in the south-central region of Arkansas, USA (the “Property”). The PEA considers the production of battery-quality lithium carbonate through a phased build-out to a total 20,900 tonnes per annum (tpa) from the contemplated joint venture with Lanxess Corp. (see press release dated November 12, 2018) at their three-operating bromine-processing plants. The PEA also includes the reclassification of the existing mineral resource to an Indicated category. The PEA was prepared by Advisian, the consulting arm of WorleyParsons Canada Services Ltd (Worley), a world-leading integrated engineering firm with extensive experience in the design and construction of chemical plants and lithium brine processing projects around the globe. Ke